Home / Market News / $GOSS
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Wedbush Adjusts Price Target on Gossamer Bio

Nov 11, 2026, 2:18 PM UTC · Primary ticker $GOSS

Wedbush has significantly lowered its price target for Gossamer Bio from $80 to $32, while maintaining a Neutral rating. This substantial reduction in the price target indicates a revised, less optimistic outlook on the company's future valuation by a prominent analyst firm, likely impacting investor sentiment negatively in the short term.

Wedbush, a notable investment bank, has drastically cut its price target for Gossamer Bio (GOSS) from $80 to $32. This 60% reduction, while maintaining a 'Neutral' rating, signals a significant re-evaluation of the company's prospects or underlying valuation by the analyst. This news is primarily negative for current GOSS shareholders as it suggests a lower perceived intrinsic value for the stock. In the short term, this could lead to downward pressure on GOSS's stock price as investors react to the revised outlook. The long-term implications depend on the reasons behind Wedbush's adjustment, which are not disclosed in this filing but could relate to clinical trial outcomes, market competition, or financial performance. A key risk for traders is potential further downside if other analysts follow suit or if the underlying reasons for the price target cut become public and are more severe than currently understood.

$GOSS negative Price target significantly lowered by Wedbush
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.